These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 22420967)

  • 1. Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
    Baschnagel A; Shah C; Margolis J; Nadeau L; Stein J; Jury R; Robertson JM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e331-5. PubMed ID: 22420967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
    Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Crane CH; Abbruzzese JL; Evans DB; Wolff RA; Ballo MT; Delclos M; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong AB; Phan T; Nguyen Q; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1293-302. PubMed ID: 11955742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
    Merrell KW; Haddock MG; Quevedo JF; Harmsen WS; Kendrick ML; Miller RC; Hallemeier CL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):561-70. PubMed ID: 26867884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
    Habermehl D; Brecht IC; Bergmann F; Rieken S; Werner J; Büchler MW; Springfeld C; Jäger D; Debus J; Combs SE
    World J Surg Oncol; 2015 Apr; 13():149. PubMed ID: 25889749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer.
    Huang PI; Chao Y; Li CP; Lee RC; Chi KH; Shiau CY; Wang LW; Yen SH
    Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):159-65. PubMed ID: 18508203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
    Allen AM; Zalupski MM; Robertson JM; Eckhauser FE; Simone D; Brown D; Hejna G; Normolle D; Lawrence TS; McGinn CJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1461-7. PubMed ID: 15275733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
    Taira K; Boku N; Fukutomi A; Onozawa Y; Hironaka S; Yoshino T; Yasui H; Yamazaki K; Taku K; Hashimoto T; Nishimura T
    J Gastroenterol; 2008; 43(11):875-80. PubMed ID: 19012041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
    Short M; Goldstein D; Halkett G; Reece W; Borg M; Zissiadis Y; Kneebone A; Spry N
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):157-62. PubMed ID: 22543205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Golden DW; Novak CJ; Minsky BD; Liauw SL
    Radiat Oncol; 2012 Sep; 7():156. PubMed ID: 22974515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
    Hattangadi JA; Hong TS; Yeap BY; Mamon HJ
    Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
    Kachnic LA; Shaw JE; Manning MA; Lauve AD; Neifeld JP
    Int J Cancer; 2001 Apr; 96(2):132-9. PubMed ID: 11291097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
    Demols A; Peeters M; Polus M; Honoré P; Boterberg T; Gay F; Closon MT; Van Houtte P; Closset J; Van Laethem JL
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1351-6. PubMed ID: 16029792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
    Abrams RA; Winter KA; Regine WF; Safran H; Hoffman JP; Lustig R; Konski AA; Benson AB; Macdonald JS; Rich TA; Willett CG
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):809-16. PubMed ID: 21277694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
    Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
    J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
    Toyama Y; Yoshida S; Saito R; Kitamura H; Okui N; Miyake R; Ito R; Son K; Usuba T; Nojiri T; Yanaga K
    World J Surg Oncol; 2013 Jan; 11():3. PubMed ID: 23302293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
    Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.